Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines
Key Clinical Message Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-04-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.2076 |
| id |
doaj-a1989da21e88475ba8414beb803a9355 |
|---|---|
| record_format |
Article |
| spelling |
doaj-a1989da21e88475ba8414beb803a93552020-11-24T21:52:49ZengWileyClinical Case Reports2050-09042019-04-017472372510.1002/ccr3.2076Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelinesMaiko Yokoyama0Gyohei Egawa1Takamitsu Makino2Kiyofumi Egawa3Division of Dermatology Amakusa Hosipital Amakusa JapanDepartment of Dermatology, Graduate School of Medicine Kyoto University Kyoto JapanDepartment of Dermatology and Plastic Surgery, Faculty of Life Sciences Kumamoto University Kumamoto JapanDivision of Dermatology, Amakusa Dermatology and Internal Medicine Clinic Kamiamakusa JapanKey Clinical Message Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course to prevent the relapse.https://doi.org/10.1002/ccr3.2076carcinoma in situerythroplasia of Queyratimiquimodregimen guideline |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Maiko Yokoyama Gyohei Egawa Takamitsu Makino Kiyofumi Egawa |
| spellingShingle |
Maiko Yokoyama Gyohei Egawa Takamitsu Makino Kiyofumi Egawa Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines Clinical Case Reports carcinoma in situ erythroplasia of Queyrat imiquimod regimen guideline |
| author_facet |
Maiko Yokoyama Gyohei Egawa Takamitsu Makino Kiyofumi Egawa |
| author_sort |
Maiko Yokoyama |
| title |
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines |
| title_short |
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines |
| title_full |
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines |
| title_fullStr |
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines |
| title_full_unstemmed |
Erythroplasia of Queyrat treated with imiquimod 5% cream: The necessity of regimen guidelines |
| title_sort |
erythroplasia of queyrat treated with imiquimod 5% cream: the necessity of regimen guidelines |
| publisher |
Wiley |
| series |
Clinical Case Reports |
| issn |
2050-0904 |
| publishDate |
2019-04-01 |
| description |
Key Clinical Message Development of noninvasive treatments for erythroplasia of Queyrat, a carcinoma in situ, is expected. This case suggests topical imiquimod might be a candidate with regimens consisting of much longer duration of the treatment than for genital warts and the maintenance phase of the treatment course to prevent the relapse. |
| topic |
carcinoma in situ erythroplasia of Queyrat imiquimod regimen guideline |
| url |
https://doi.org/10.1002/ccr3.2076 |
| work_keys_str_mv |
AT maikoyokoyama erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines AT gyoheiegawa erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines AT takamitsumakino erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines AT kiyofumiegawa erythroplasiaofqueyrattreatedwithimiquimod5creamthenecessityofregimenguidelines |
| _version_ |
1725874741028323328 |